These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 29369798)
21. Nuclear Localization of BRAF Zerfaoui M; Toraih E; Ruiz E; Errami Y; Attia AS; Krzysztof M; Abd Elmageed ZY; Kandil E Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053476 [TBL] [Abstract][Full Text] [Related]
22. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients. Tas F; Erturk K Neoplasma; 2019 Jul; 66(4):631-636. PubMed ID: 31058533 [TBL] [Abstract][Full Text] [Related]
23. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539 [TBL] [Abstract][Full Text] [Related]
24. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. Walter L; Heinzerling L Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057 [TBL] [Abstract][Full Text] [Related]
25. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
26. miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma. Luo M; Wu L; Zhang K; Wang H; Wu S; O'Connell D; Gao T; Zhong H; Yang Y Cell Signal; 2018 Jan; 42():30-43. PubMed ID: 28982601 [TBL] [Abstract][Full Text] [Related]
27. Dabrafenib therapy for advanced melanoma. Trinh VA; Davis JE; Anderson JE; Kim KB Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661 [TBL] [Abstract][Full Text] [Related]
29. The plasma membrane Ca Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079 [TBL] [Abstract][Full Text] [Related]
30. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor. Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109 [TBL] [Abstract][Full Text] [Related]
31. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Kim A; Cohen MS Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499 [TBL] [Abstract][Full Text] [Related]
32. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma. Seeley AR; De Los Santos JF; Conry RM Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037 [TBL] [Abstract][Full Text] [Related]
33. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
34. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]
35. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
36. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients? Schirosi L; Strippoli S; Gaudio F; Graziano G; Popescu O; Guida M; Simone G; Mangia A BMC Cancer; 2016 Nov; 16(1):905. PubMed ID: 27863476 [TBL] [Abstract][Full Text] [Related]